NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









Integrated Nanotherapeutics

Integrated Nanotherapeutics

Private
Burnaby, British ColumbiaHealthcare & Life Scienceshttps://integratedntx.com/

Last Round

Grant

Mar 18, 2026

Total Funding Raised

$140,000

Momentum

Top 50%

of companies Caplight tracks

Company Overview

Integrated Nanotherapeutics is a biotechnology company that is developing a new class of therapeutics for antigen-specific immune tolerance using its proprietary multi-cargo lipid nanoparticles (LNPs) platform.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Precision Medicine, Clinical Trials

Business Model

B2B

Customer Profile

Services & Consulting, Revenue Share, Government Contracts

AI Layer

Non-AI

Keywords

immune tolerance therapylipid nanoparticle platformLNPmRNA therapyautoimmune disease treatmentType 1 Diabetes treatmentinverse vaccineantigen-specific immunotherapymulti-cargo deliverydrug delivery platformT1D therapypreclinical biotech

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Integrated Nanotherapeutics Comparables

Compare Integrated Nanotherapeutics with similar companies based on industry and business-model similarity.

Integrated Nanotherapeutics comparables — related companies by embedding similarity
CompanySimilarityMarket Cap

View Full Comparables Set

Access detailed peer comparisons, similarity scores, and market data.

Integrated Nanotherapeutics Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
GrantMar 18, 2026
GrantSep 9, 2024
AcceleratorJun 1, 2023
AcceleratorApr 1, 2023
GrantMar 18, 2019

Integrated Nanotherapeutics Investors

Notable investors and investment history

Market signals

Structured signals derived from secondary market and firmographic data.

  • Apr 21, 2026

    Monthly visitors increased 90% MoM.

  • Mar 18, 2026

    Received grant funding from Genome British Columbia and Genome Canada.

Integrated Nanotherapeutics Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Integrated Nanotherapeutics Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Integrated Nanotherapeutics's valuation, stock price, and market status.

Firmographic Details

HeadquartersBurnaby, British Columbia
Employee Range14
Year Founded2014
Last FundingMar 18, 2026

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.